FinTech
Antisense Therapeutics: Starts dosing monkeys in ATL1102 toxicology study
Antisense Therapeutics Starts dosing monkeys in ATL1102 toxicology studyAntisense Therapeutics (ANP) commences the dosing stage of a nine-month chronic monkey toxicology study of...
FinTech
Antisense Therapeutics: Receives first approval for phase two DMD clinical trial
Antisense Therapeutics Receives first approval for phase two DMD clinical trialAntisense Therapeutics (ANP) receives approval to conduct its phase two trial in non-ambulant...
FinTech
Antisense Therapeutics: Shares rise on long COVID-19 study
Antisense Therapeutics Shares rise on long COVID-19 studyAntisense Therapeutics (ANP) announces the outcomes of its collaboration to study the neurological aspects of long...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
